Lisinopril is the more likely culprit for hyponatremia in this 86-year-old female, though both medications warrant consideration
Lisinopril, even at the low dose of 2.5 mg, can cause hyponatremia through syndrome of inappropriate antidiuretic hormone secretion (SIADH), and this risk is particularly elevated in elderly women. While Janumet (metformin/sitagliptin) is not typically associated with electrolyte disturbances of this nature, lisinopril has well-documented case reports of causing severe hyponatremia in older adults.
Primary Mechanism: ACE Inhibitors and SIADH
ACE inhibitors like lisinopril can paradoxically cause hyponatremia despite their antihypertensive mechanism. The proposed mechanism involves blocking peripheral conversion of angiotensin I to angiotensin II while allowing increased circulating angiotensin I to enter the brain, where it converts to angiotensin II, stimulating both thirst and ADH release from the hypothalamus 1. This ultimately leads to water retention and dilutional hyponatremia.
Key Clinical Evidence
Multiple case reports document severe hyponatremia with lisinopril:
- A 76-year-old woman developed sodium of 109 mEq/L on lisinopril 20 mg, which corrected after discontinuation and remained normal for 32 months despite continuing other medications 1
- A 63-year-old woman presented with seizures and sodium of 101 mEq/L on lisinopril, which resolved after stopping the drug 2
- Another 63-year-old woman's sodium dropped from 134 to 126 mEq/L when lisinopril was restarted after initial discontinuation 3
The critical pattern: hyponatremia resolved upon lisinopril discontinuation and did not recur, establishing causality.
Risk Factors Present in This Patient
This 86-year-old female has multiple risk factors for ACE inhibitor-induced hyponatremia:
- Advanced age: Elderly patients have greater susceptibility to ACE inhibitor effects 4
- Female sex: Women, particularly elderly women, are at highest risk 5
- Age >80 years: Thiazide-associated hyponatremia risk peaks in women aged 80+ 5, and similar age-related vulnerability likely applies to ACE inhibitors
Guidelines specifically mandate monitoring electrolytes within 1-2 weeks of ACE inhibitor initiation, with dose increases, and at least yearly 4. For patients over 80, more frequent monitoring is recommended 4.
Janumet (Metformin/Sitagliptin) Considerations
Janumet is not a typical cause of hyponatremia or hypochloremia:
Metformin Component
- Primary concern is lactic acidosis, not electrolyte disturbances 6
- In this 86-year-old patient, metformin requires careful renal monitoring due to age-related decline in kidney function 4
- For patients ≥80 years, creatinine clearance measurement (not just serum creatinine) should be obtained 4
- The FDA label emphasizes renal function assessment but does not list hyponatremia as a recognized adverse effect 6
Sitagliptin Component
- No established association with hyponatremia or hypochloremia
- Main electrolyte concern is hyperkalemia when combined with ACE inhibitors, not hyponatremia 4
Hypochloremia Pattern
Hypochloremia typically accompanies hyponatremia in SIADH because both sodium and chloride are diluted by excess water retention 7. The concurrent low sodium and chloride strongly suggests:
- SIADH (most likely from lisinopril)
- Volume status assessment is critical: check for euvolemia with inappropriately concentrated urine (urine osmolality >100 mOsm/kg, urine sodium >30 mmol/L) 7
Diagnostic Approach
Immediate steps:
- Measure serum osmolality, urine osmolality, and urine sodium
- Assess volume status clinically (skin turgor, jugular venous pressure, orthostatic vitals) 7
- Check thyroid and adrenal function to exclude other causes 7
- Review medication timing: when was lisinopril started or dose increased?
- Calculate fractional excretion of uric acid (FEUA) if diagnosis unclear—FEUA >12% supports SIADH 7
Management Algorithm
If SIADH from lisinopril is confirmed:
- Discontinue lisinopril 1, 2, 3
- Initiate fluid restriction (500-1000 mL/day initially) 1, 8
- Monitor sodium closely—expect gradual correction over days
- Switch to alternative antihypertensive (consider calcium channel blocker or ARB, though ARBs may carry similar risk)
- Do not restart lisinopril—documented cases show recurrence upon rechallenge 3
For Janumet management in this elderly patient:
- Continue if eGFR ≥45 mL/min/1.73 m² 6
- Reduce sitagliptin to 50 mg daily if eGFR 30-45 mL/min/1.73 m² 6
- Discontinue if eGFR <30 mL/min/1.73 m² 6
- Obtain creatinine clearance measurement given age >80 4
Critical Pitfalls to Avoid
- Do not assume the low 2.5 mg dose of lisinopril is "too low" to cause problems—case reports document severe hyponatremia at standard doses 1, 2
- Do not overlook drug-drug interactions: if patient is on other medications that impair free water excretion (SSRIs, NSAIDs, diuretics), risk compounds 9, 10
- Do not correct sodium too rapidly—risk of osmotic demyelination syndrome, especially in chronic hyponatremia 8
- Do not continue ACE inhibitor if SIADH is documented—switching to another ACE inhibitor will not solve the problem 1
Monitoring After Resolution
Once hyponatremia resolves:
- Check sodium monthly for 3 months on new antihypertensive regimen
- Continue Janumet with annual renal function monitoring (more frequently given age >80) 4, 6
- Document the lisinopril reaction clearly to prevent future re-exposure
The evidence strongly implicates lisinopril as the cause of both low sodium and chloride in this elderly female patient, with multiple case reports demonstrating causality through discontinuation and rechallenge. Janumet should be continued with appropriate renal monitoring but is unlikely to be the primary culprit for these specific electrolyte abnormalities.